Penumbra Inc (NYSE:PEN) EVP Robert D. Evans sold 10,000 shares of the stock in a transaction dated Monday, March 12th. The stock was sold at an average price of $121.03, for a total value of $1,210,300.00. Following the transaction, the executive vice president now owns 12,225 shares of the company’s stock, valued at $1,479,591.75. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link.
Penumbra Inc (PEN) traded down $0.50 during mid-day trading on Wednesday, reaching $122.70. The company’s stock had a trading volume of 268,778 shares, compared to its average volume of 290,442. The company has a market capitalization of $4,133.26, a P/E ratio of 1,115.56, a price-to-earnings-growth ratio of 44.04 and a beta of 0.06. Penumbra Inc has a 12-month low of $76.15 and a 12-month high of $124.85.
PEN has been the subject of a number of research reports. BMO Capital Markets downgraded Penumbra from an “outperform” rating to a “market perform” rating and decreased their price objective for the stock from $117.00 to $110.00 in a report on Tuesday, December 12th. They noted that the move was a valuation call. JPMorgan Chase & Co. downgraded Penumbra from an “overweight” rating to a “neutral” rating in a report on Tuesday, January 2nd. Zacks Investment Research downgraded Penumbra from a “hold” rating to a “sell” rating in a report on Wednesday, January 10th. Canaccord Genuity reiterated a “buy” rating and set a $113.00 price objective on shares of Penumbra in a report on Wednesday, January 24th. Finally, William Blair started coverage on Penumbra in a report on Wednesday, February 21st. They set an “outperform” rating for the company. Four analysts have rated the stock with a hold rating and three have assigned a buy rating to the company’s stock. Penumbra presently has a consensus rating of “Hold” and a consensus price target of $126.00.
TRADEMARK VIOLATION WARNING: “Robert D. Evans Sells 10,000 Shares of Penumbra Inc (PEN) Stock” was published by American Banking News and is the property of of American Banking News. If you are reading this piece of content on another domain, it was illegally copied and republished in violation of international copyright & trademark law. The legal version of this piece of content can be read at https://www.americanbankingnews.com/2018/03/14/robert-d-evans-sells-10000-shares-of-penumbra-inc-pen-stock.html.
Penumbra, Inc is a healthcare company focused on interventional therapies. The Company designs, develops, manufactures and markets medical devices. It has a portfolio of products that addresses medical conditions and clinical needs across two markets, neuro and peripheral vascular. The conditions that its products address include ischemic stroke, hemorrhagic stroke and various peripheral vascular conditions that can be treated through thrombectomy and embolization procedures.
Receive News & Ratings for Penumbra Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Penumbra and related companies with MarketBeat.com's FREE daily email newsletter.